Trovagene, Inc. TROV Cash Flow

Trovagene, inc. (TROV)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating activities
Net Income (Loss) Attributable to Parent
-16,597	-16,414	-16,330	-15,958	-15,579	-16,461	-14,872	-15,394	-19,693	-24,906	-30,884	-36,784	-38,940	-39,203	-38,036	-30,581	-30,559	-27,471	-24,773	-27,413	-18,310	-14,325	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment loss
-	-	-	-	-	-	-	-	-	589	485	485	485	0	0	0	0	-	-	-	-	-	-	-	-
Net gain on disposal of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Depreciation and amortization
486	494	287	463	733	859	992	1,085	1,169	1,247	1,333	1,225	1,243	1,069	821	715	467	378	315	276	249	234	0	0	0
Stock-based compensation expense
862	884	884	896	968	2,174	2,800	3,943	4,497	4,012	4,679	5,087	5,614	7,504	7,129	6,223	6,045	3,946	3,444	2,926	2,222	2,070	0	0	0
Accretion of final fee premium
-	-	-	-	-	-	-	-	-	293	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of discount on debt
-	-	-	-	-	-	-	-	-	113	181	234	148	173	198	205	314	346	0	0	0	-	-	-	-
Amortization of discount on debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	87	88	0	0	0	-	-	-	-
Amortization of premiums on short-term investments
-	-	-	-	-	-	-	-	-	-9	-54	-89	-118	-107	0	0	0	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-59	199	167	154	140	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Interest income accrued on short-term investments
-	-	-	-	-	-	-	-	-	90	184	99	-67	84	0	0	0	-	-	-	-	-	-	-	-
Unrealized Gain (Loss) on Derivatives
40	28	65	49	737	617	1,967	3,498	2,715	3,401	3,800	2,359	2,483	2,462	1,053	4,982	1,754	-726	-900	-5,946	-553	1,425	0	0	0
Release of clinical trial funding commitment
925	703	509	310	70	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Other assets
69	54	-78	-143	8	23	0	0	0	-	-	-	-	789	24	8	34	37	0	0	0	-	-	-	-
Accounts receivable and unbilled receivable
-9	35	23	-1	1	-19	-159	-143	-75	-23	92	-1	18	1	-203	58	2	42	225	39	-69	-22	0	0	0
Prepaid expenses
8	-115	17	5	-103	-21	-90	260	221	208	102	-54	115	277	550	369	422	420	47	212	155	216	0	0	0
Operating lease right-of-use assets
-309	-302	-467	-309	-73	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
1,539	1,455	668	-37	167	214	-649	-2,582	-2,529	-2,940	-2,241	956	724	2,157	2,235	1,814	1,817	361	711	507	234	632	0	0	0
Operating lease liabilities
-796	-776	-576	-379	-186	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-16,032	-17,379	-23,281	-28,954	-29,401	-32,882	-31,039	-28,843	-26,935	-24,301	-22,119	-19,176	-17,452	-14,661	-12,727	0	0	0
Investing activities:
Capital expenditures
62	67	67	5	5	5	-30	85	94	101	161	173	482	823	1,781	2,223	2,345	2,241	1,384	917	491	363	0	0	0
Maturities of short-term investments
-	-	-	-	-	-	-	-	-	16,431	30,181	30,181	27,750	13,750	0	0	0	-	-	-	-	-	-	-	-
Purchases of short-term investments
-	-	-	-	-	-	-	-	-	8,804	22,113	18,613	46,564	37,760	0	0	0	-	-	-	-	-	-	-	-
Net cash used in investing activities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-115	18,773	23,962	24,341	27,829	-19,297	-24,833	-26,225	-30,167	-2,338	-2,233	-1,321	-854	-428	-299	0	0	0
Financing activities:
Proceeds from sales of common stock and warrants
9,817	8,817	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	61,215	0	0	0	-	-	-	-
Costs related to the clinical trial funding commitment
0	-40	-40	-40	-40	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net borrowings under debt agreements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Proceeds from exercise of warrants
1,473	3,299	3,291	3,300	3,445	1,612	1,612	1,612	1,449	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of options
-	-	-	-	-	-	-	-	-	-	-	-	-	366	409	528	758	860	0	0	0	-	-	-	-
Borrowings under equipment line of credit
-	-	-	-	-	-	-	-	-	-	-	-	-	792	1,878	1,878	1,636	1,086	0	0	0	-	-	-	-
Repayments under equipment line of credit
-	-	-	-	-	1,200	1,356	1,513	626	626	521	365	208	52	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net change in cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of long-term debt
-	-	-	-	-	-	-	-	-	-	-	-	-	8,896	8,896	2,320	919	0	0	0	0	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	26,844	-4,928	-6,378	-10,508	-13,222	2,380	2,301	3,490	38,390	42,633	64,551	63,484	24,926	36,214	14,484	0	0	0
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	7	-13	-0	-6	-5	-1	-2	-0	0	0	0	0	-	-	-	-
Net change in cash and cash equivalents
-	-	-	-	-	-	-	10,702	-3,526	-5,689	-15,134	-14,795	-49,805	-53,577	-51,580	-18,714	15,993	40,199	42,986	6,619	21,124	1,456	0	0	0
Supplementary disclosure of cash flow activity:
Cash paid for taxes
0	0	0	0	1	0	0	0	0	-	-	-	-	-	-	-	-	16	0	0	0	2	0	0	0
Cash paid for interest
-	-	-	-	-	-	-	60	384	668	947	1,196	1,127	1,103	1,072	1,068	1,073	1,061	972	883	683	425	0	0	0
Supplemental disclosure of non-cash investing and financing activities:
Preferred stock dividend payable on Series A Convertible Preferred Stock
24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	19	23	0	0	0
Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock
0	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment
0	1,675	1,675	1,675	1,675	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt costs and final payment
-	-	-	-	-	-	-	-	-	113	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Leasehold improvements paid for by lessor
-	-	-	-	-	-	-	-	-	-	-	-	-	1,860	1,860	1,860	1,860	0	0	0	0	-	-	-	-